Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Authors : Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart-Gebhart M
Year : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pages : 1758835919827714

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Authors : Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Daidone MG
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3887-3895

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Authors : Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, Tkint de Roodenbeke D, Willard-Gallo K
Year : 2019
Journal : Cancer Lett
Volume : 450
Pages : 88-97

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Authors : Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 1056-62

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Authors : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Year : 2018
Journal : Int J Oncol
Volume : 52(2)
Pages : 424-432

Reply to The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al."

Authors : Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B
Year : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 281-282

Toxicity Adjustment in the ESMO-MCBS: A diligent process of data interpretation with peer review that is far from Gestalt"."

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2018
Journal : Ann Oncol
Volume : 29(2)
Pages : 521-522

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

Authors : Viale G, de Snoo FA, Slaets L, Bogaerts J, van t Veer L, Rutgers EJ, Piccart-Gebhart M, Stork-Sloots L, Glas A, Russo L, DellOrto P, Tryfonidis K, Litière S, Cardoso F
Year : 2018
Journal : Breast Cancer Res Treat
Volume : 167(1)
Pages : 123-131

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

Authors : Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, Berlière M, Piccart-Gebhart M, Sotiriou C, Sosnowski M, Forget P, Biganzoli E
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(10)
Pages : 1115-1122

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2151

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2152

Reply to ESMO-MCBS v1.1: Statistical and Patient Relevant Shortcomings" by R. Emprechtinger et al."

Authors : Cherny NI, Dafni U, Piccart-Gebhart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE
Year : 2018
Journal : Ann Oncol
Volume : 29(5)
Pages : 1335-1338

Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.

Authors : Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Pritchard KI, Gelber Rd, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart M, Dowsett M
Year : 2018
Journal : Clin Cancer Res
Volume : 24(13)
Pages : 3079-3086

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Authors : Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber Rd, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA
Year : 2018
Journal : Int J Radiat Oncol Biol Phys
Volume : 101(2)
Pages : 316-324.

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110
Pages : 1142-1143

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.

Authors : Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart-Gebhart M
Year : 2018
Journal : Breast
Volume : 39
Pages : 14-18

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Authors : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pages : 23

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

Authors : Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M
Year : 2018
Journal : Bull Cancer
Volume : 105
Pages : 842-846

The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe.

Authors : Soria JC, Baselga J, Piccart-Gebhart M
Year : 2018
Journal : Ann Oncol
Volume : 29
Pages : 1887-1888

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Authors : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Year : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783